This company listing is no longer active
Vifor Pharma Crecimiento futuro
Future controles de criterios 1/6
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 15.0% |
Tasa de crecimiento de los ingresos | 8.7% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2024 | 2,353 | N/A | N/A | N/A | 1 |
12/31/2023 | 2,189 | N/A | N/A | N/A | 1 |
12/31/2022 | 1,977 | N/A | N/A | N/A | 1 |
12/31/2021 | 1,812 | 147 | 414 | 527 | N/A |
6/30/2021 | 1,753 | 213 | 169 | 441 | N/A |
3/31/2021 | 1,757 | 176 | 119 | 432 | N/A |
12/31/2020 | 1,762 | 139 | 70 | 424 | N/A |
6/30/2020 | 1,709 | 93 | 301 | 500 | N/A |
3/31/2020 | 1,732 | 101 | 350 | 512 | N/A |
12/31/2019 | 1,754 | 108 | 399 | 525 | N/A |
9/30/2019 | 1,845 | 129 | 280 | 439 | N/A |
6/30/2019 | 1,784 | 100 | 169 | 353 | N/A |
3/31/2019 | 1,711 | 126 | 44 | 274 | N/A |
12/31/2018 | 1,639 | 152 | -82 | 194 | N/A |
9/30/2018 | 1,571 | 157 | -110 | 132 | N/A |
6/30/2018 | 1,504 | 162 | -139 | 70 | N/A |
3/31/2018 | 1,441 | 98 | -83 | 65 | N/A |
12/31/2017 | 1,378 | 34 | -28 | 60 | N/A |
9/30/2017 | 1,345 | 26 | -15 | 90 | N/A |
6/30/2017 | 1,312 | 18 | -2 | 120 | N/A |
3/31/2017 | 1,283 | 82 | 4 | 190 | N/A |
12/31/2016 | 1,254 | 147 | 10 | 259 | N/A |
9/30/2016 | 1,944 | 218 | 139 | 418 | N/A |
6/30/2016 | 2,635 | 290 | 267 | 577 | N/A |
3/31/2016 | 3,265 | 295 | 312 | 550 | N/A |
12/31/2015 | 3,896 | 301 | 358 | 522 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if 0RPD's forecast earnings growth is above the savings rate (1%).
Beneficios vs. Mercado: Insufficient data to determine if 0RPD's earnings are forecast to grow faster than the UK market
Beneficios de alto crecimiento: Insufficient data to determine if 0RPD's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: 0RPD's revenue (8.7% per year) is forecast to grow faster than the UK market (4.2% per year).
Ingresos de alto crecimiento: 0RPD's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 0RPD's Return on Equity is forecast to be high in 3 years time